Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Axis™ Allograft Dermis for Female Pelvic Floor Repair: a Prospective Post Market Study

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Coloplast A/S Identifier:
First received: February 17, 2012
Last updated: June 28, 2016
Last verified: June 2016
This study is a prospective, single arm, multi-center, post-market study to evaluate the efficacy of Axis™ Allograft Dermis used for anterior, posterior or combined (anterior and posterior) pelvic organ prolapse repair.

Condition Intervention
Pelvic Organ Prolapse
Other: Axis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Axis™ Allograft Dermis for Female Pelvic Floor Repair: a Prospective Post Market Study

Resource links provided by NLM:

Further study details as provided by Coloplast A/S:

Primary Outcome Measures:
  • Evaluate efficacy of the Axis Dermis graft used for soft tissue repair, replacement, reconstruction, or augmentations in the correction of POP as assessed by POP-Q Stage improvement [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Assess change in prolapse stage from baseline [ Time Frame: 6 weeks, 6 months, 2 years, 3 years ] [ Designated as safety issue: No ]
    Determined by POP-Q prolapse grading

  • Patient satisfaction and quality of life measurement [ Time Frame: 6 weeks, 6 months, 2 years, 3 years ] [ Designated as safety issue: No ]
    Measured through patient questionnaires PFDI-20, PFIQ-7, PISQ-12, PGI-I, SSQ-8, and Pelvic and Sexual Health VAS

  • Summary of AEs graded as mild, moderate, severe possibly or related to product and/or procedure and SAEs related to product and/or procedure [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Enrollment: 74
Study Start Date: November 2011
Estimated Study Completion Date: September 2018
Estimated Primary Completion Date: September 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Axis Other: Axis
Coloplast's Axis™ Allograft Dermis consists of solvent-dehydrated, gamma-irradiated, preserved human collagen. It is restricted to homologus use as a soft tissue graft for horizontal and vertical soft tissue augmentation of thickness and length.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The study population will be adult female patients with pelvic organ prolapse, POP-Q Stage ≥ 2 that are clinically indicated for surgical intervention with Axis human tissue in the anterior, posterior, or combined (anterior and posterior) compartments at the institutions designated for this study.

Inclusion Criteria:

  • Adult female at least 18 years of age.
  • Willing and able to provide written informed consent.
  • Confirmed pelvic organ prolapse (POP) of Stage 2 or higher as determined by POP-Q prolapse grading requiring surgical intervention in the anterior, posterior or combined (anterior and posterior) compartment.
  • Willing and able to complete all follow-up visits and procedures indicated in this protocol.

Exclusion Criteria:

  • Concurrent surgical treatment of pelvic organ prolapse using anything other than the Axis Dermis.[Note: concurrent mid-urethral sling placement for treatment of stress urinary incontinence is allowed].
  • Confirmed Stage 2 or higher prolapse as determined by POP-Q prolapse grading for a compartment that is not being repaired in the same procedure. (Concurrent POP-Q Stage 1 repair is at the physician's discretion.)
  • Previous pelvic organ prolapse repair using biologic, or synthetic grafts. [Note: previous midurethral sling for treatment of stress urinary incontinence is allowed]
  • Pregnant or a desire to become pregnant in the future.
  • Previous radiation or other treatments for cancer in the pelvic area.
  • Severe urogenital atrophy.
  • Immunosuppression and/or current systemic steroid user.
  • Any contraindication to the surgical procedure.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01541748

United States, Florida
Cleveland Clinic Florida
Weston, Florida, United States, 33331
United States, Massachusetts
Boston Urogynecology Associates
Cambridge, Massachusetts, United States, 02138
United States, Michigan
Female Pelvic Medicine and Urogynecology Institute of MI
Grand Rapids, Michigan, United States, 49503
United States, Pennsylvania
The Institute for Female Pelvic Medicine and Reconstructive Surgery
Allentown, Pennsylvania, United States, 18103
Philadelphia Urosurgical Associates
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Coloplast A/S
Principal Investigator: Kristine Whitmore, MD Philadelphia Urosurgical Associates
  More Information

Responsible Party: Coloplast A/S Identifier: NCT01541748     History of Changes
Other Study ID Numbers: CP009SU 
Study First Received: February 17, 2012
Last Updated: June 28, 2016
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Pelvic Organ Prolapse
Pathological Conditions, Anatomical processed this record on October 20, 2016